Skip to main content

Table 3 Evolution of plasma TAG and NEFA (measured in the post-absorptive state) in control rats and in ZDF rats receiving or not fenofibrate (F) or metformin (M).

From: Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model – the Zucker diabetic rat

TAG mM Control ZDF ZDF + F ZDF + M
7 weeks 0.47 ± 0.04 4.12 ± 0.48 ***   
14 weeks 0.50 ± 0.07 3.79 ± 0.40 *** 2.97 ± 0.77 **$ 1.48 ± 0.42 *$$
21 weeks 0.54 ± 0.04 5.83 ± 1.01 *** 3.26 ± 0.40 ***$ 2.40 ± 0.50 **$
NEFA μM     
7 weeks 595 ± 71 491 ± 28   
14 weeks 512 ± 59 1150 ± 95 ** 985 ± 68 ** 1052 ± 59 **
21 weeks 485 ± 63 1495 ± 152 *** 1310 ± 152 *** 1158 ± 125 ***
  1. Results are shown are mean and sem. ** p < 0.01, *** p < 0.001 vs the corresponding control; $ p < 0.05, $$ p < 001 vs the corresponding ZDF group. These parameters were measured only in rats sacrificed for tissue sampling (n = 5 for each group), therefore they were measured at 7 weeks only in a group of 5 control and ZDF rats.